Knight Therapeutics Submits GEMTESA® for Canadian Approval
Event summary
- Knight Therapeutics' New Drug Submission (NDS) for GEMTESA® (vibegron) accepted for review by Health Canada on September 15, 2026.
- GEMTESA® targets overactive bladder (OAB) symptoms in adults and OAB with benign prostatic hyperplasia (BPH) in adult males.
- Knight entered exclusive supply and distribution agreements with Sumitomo Pharma America in June 2025 for GEMTESA®, ORGOVYX®, and MYFEMBREE® in Canada.
- Phase 3 COURAGE and EMPOWUR trials demonstrated significant efficacy of GEMTESA® in reducing OAB symptoms.
The big picture
Knight Therapeutics' submission of GEMTESA® for Canadian approval marks a strategic step in expanding its portfolio of innovative therapies. The move aligns with broader industry trends of targeting underserved populations, such as men with OAB and BPH, where treatment options are often misattributed to normal aging. The company's partnership with Sumitomo Pharma America underscores a focus on leveraging external expertise to accelerate market access and commercialization in the pan-American region.
What we're watching
- Regulatory Timing
- The pace at which Health Canada reviews the submission will determine GEMTESA®'s market entry timeline in Canada.
- Market Penetration
- Whether Knight can effectively commercialize GEMTESA® in a competitive Canadian OAB treatment landscape.
- Partnership Dynamics
- How the collaboration with Sumitomo Pharma America evolves beyond GEMTESA®, particularly for ORGOVYX® and MYFEMBREE®.
Related topics